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Glioblastoma multiforme (GBM) is a highly aggres-
sive form of brain cancer associated with a very
poor prognosis. Recently, the initiation and growth
of GBM has been linked to brain tumor-initiating cells
(BTICs), which are poorly differentiated and share
features with neural stem cells (NSCs). Here we
describe a kinome-wide RNA interference screen to
identify factors that control the tumorigenicity of
BTICs. We identified several genes whose silencing
induces differentiation of BTICs derived from
multiple GBM patients. In particular, knockdown of
the adaptor protein TRRAP significantly increased
differentiation of cultured BTICs, sensitized the cells
to apoptotic stimuli, and negatively affected cell
cycle progression. TRRAP knockdown also signifi-
cantly suppressed tumor formation upon intracranial
BTIC implantation into mice. Together, these find-
ings support a critical role for TRRAP in maintaining
a tumorigenic, stem cell-like state.
INTRODUCTION
Glioblastoma multiforme (GBM; WHO grade IV astrocytoma/
glioma) is the most aggressive and most common brain tumor
in adults. Most deaths occur within 2 years of diagnosis despite
advances in surgery, radiation, and chemotherapy (Grossman
and Batara, 2004). In addition to its highly brain-infiltrative
character, GBM shows a strong phenotypic and genotypic
heterogeneity, further complicating therapeutic intervention.
Recent evidence has indicated that primary brain tumors
possess a hierarchical organization of heterogeneous cell
populations, which differ in their tumor-forming potential.
Tumor-driving capacity has been attributed to poorly differenti-ated, brain tumor-initiating cells (BTICs, also termed cancer
stem cells or tumor stem cells) (Lee et al., 2006; Nakano and
Kornblum, 2006; Singh et al., 2003). BTICs share several
features with neural stem cells (NSCs) including the expression
of neural markers such as Nestin and Sox2 (Gangemi et al.,
2008; Mangiola et al., 2007), the ability to migrate within the
brain (Sanai et al., 2005), the capacity to self-renew and to
undergo multilineage differentiation (Fael Al-Mayhani et al.,
2009; Galli et al., 2004; Lee et al., 2006; Nakano and Kornblum,
2006; Piccirillo et al., 2006; Pollard et al., 2009; Singh
et al., 2003), and responsiveness to similar signaling cues (for
example Hedgehog, Notch, and Pten/Akt signaling) (Clement
et al., 2007; Purow et al., 2005; Zheng et al., 2008). Further-
more, it has been recently reported that bone-morphogenetic
protein (BMP), as well as distinct microRNAs, can suppress
the tumorigenicity of BTICs by promoting their differentiation
(Lee et al., 2008; Piccirillo et al., 2006; Silber et al., 2008).
Thus, it may be possible to target BTICs by developing differ-
entiation-inducing therapies for GBM tumors. This approach
requires an understanding of the genes and pathways that are
involved in the maintenance of the poorly differentiated, tumor-
initiating cell state. In this study, we established and character-
ized BTICs from several primary GBM tumors and identified
genes regulating their differentiation through an unbiased,
kinome-wide RNA interference (RNAi) screen (500 kinase
targets). To further validate the screen results, we show that
one candidate gene known as transformation/transcription
domain-associated protein (TRRAP) is required for BTIC tumori-
genicity in vitro and in vivo.
RESULTS
In Vitro Expansion and Characterization
of Patient-Derived BTICs
To establish BTIC expansion and culture conditions suitable for
the automated imaging required for this large-scale RNAi
screen, we optimized adherent cell culture conditions thatCell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc. 37
Figure 1. Phenotypic Characterization of
BTICs
(A–F) Expression of Nestin, Sox2, and Ki67
(A and C) decreases in cultured BTICs in the pres-
ence of BMP4 (50 ng/mL; B and D) whereas
expressionofGFAPandTuJ1 increases compared
to nontreated cells (n.t., E and F); DAPI-stained
nuclei (blue). Scale bar represents 25 mm.
(G) Quantitation of cell marker expression of GBM
surgical specimens (mean, error bars represent the
standard error of the mean) grown under BTIC
conditions (blue columns), upon withdrawal of
FGF/EGF (light blue columns), upon further addi-
tion of 10% serum (dark red columns), and under
BTIC conditions plus BMP4 (red columns).
(H and I) H&E and Nestin staining on adjacent
sections detecting GBM-1-derived tumor mass
below the ventricle (V), 15weeks postimplantation.
Arrowheads illustrate tumor cells infiltrating the
corpus callosum (CC) andstriatum (S) of themouse
brain. Scale bars represent 500 mm.
(J) Higher-power image of Nestin-expressing
tumor cells within the CC. Scale bar represents
20 mm. Additional immunohistochemistry of xeno-
graft tumors is shown in Figure S1.
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of NSCs and BTICs (Gage et al., 1995; Lee et al., 2006; McKay,
1997). Under these BTIC conditions (poly-D-lysine/laminin-
coated culture dishes and Neurobasal medium supplemented
with the mitogens FGF/EGF), monolayer-cultured cells were
reproducibly derived from five different primary human GBM
specimens (GBM-1 to GBM-5; Figure S1 available online). These
maintained both distinct global gene expression patterns and
differential expression of several glioma candidate genes,
reflecting GBM tumor heterogeneity (Figure S1). We next evalu-
ated the neural stem cell-like characteristics and differentiation
properties of early culture passage GBM-derived monolayer
cells by using established in vitro and in vivo assays (Gage
et al., 1995; Lee et al., 2006, 2008; McKay, 1997; Nakano and
Kornblum, 2006). Under BTIC conditions, the majority of these
cells maintained an undifferentiated phenotype as indicated by
a high percentage of cells positive for the neural precursor/
glioma markers Nestin and Sox2 (80% and 60%, respectively;
Figures 1A and 1G) and the proliferation marker Ki67 (60%;
Figures 1C and 1G), as well as a low percentage of differentiated
cells expressing the astroglial marker GFAP (<10%) or the
neuronal marker TuJ1 (<5%; GFAP-TuJ1 double-positive cells
were <2%; Figures 1E and 1G). Upon withdrawal of the
mitogens FGF/EGF, the percentage of differentiated cells
increased by 2-fold, while a substantial cell population
remained proliferative (40% Ki67-positive cells), consistent
with an autocrine mitogenic activity reported previously for
mitogen-depleted cultures of glioma stem cells (Li et al., 2009).
Expectedly, addition of serum induced a prodifferentiation
effect of all specimen-derived cells as reflected by a 4-fold
increase of GFAP- or TuJ1-positive cells and a concurrent
reduction of Nestin, Sox2, and Ki67 immunoreactivity (Fig-
ure 1G). Addition of the cytokine BMP4 (50 nM) to the FGF/
EGF-containing BTIC medium elicited a differentiation pheno-
type in all specimens at a level comparable to mitogen-depleted,
serum-treated cultures.38 Cell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc.Patient-Derived BTIC Xenograft Tumors Show
Characteristics of High-Grade Gliomas
To evaluate the in vivo tumorigenicity of the patient-derived
monolayer cultured cells, they were genetically tagged with
firefly luciferase (F-luc) and their growth wasmonitored by nonin-
vasive bioluminescence imaging after implantation into the
forebrain of CB17/SCID mice (Figure S1). Injection of 10,000 or
30,000 early passage cells led to efficient tumor growth over
15weeks in 100%of the cases. Subsequent histological analysis
and staining for GFAP, Ki67, and human-specific Nestin
confirmed a large tumor burden in animals 15 weeks after
implantation (Figures 1H–1J; Figure S1). Importantly, the xeno-
graft tumors showed characteristics of high-grade gliomas
including high cellularity, tumor heterogeneity, proliferation,
and massive infiltration into areas adjacent to the implantation
site and even into relatively distant brain areas (e.g., the olfactory
bulbs). In line with recent reports (Fael Al-Mayhani et al., 2009;
Lee et al., 2006; Pollard et al., 2009), our findings indicate
a stem cell-like and tumor-initiating character of monolayer-
cultured specimen-derived BTICs, which also reflect hallmark
features of human brain tumors in the xenograft model.
A Kinome-wide RNAi Screen for Induced BTIC
Differentiation
We next established a quantifiable assay of BTIC differentiation
suitable for a high-throughput RNAi screen. BTICs were grown
in precoated 384-well microtiter plates (1000 cells/well)
and transduced with lentiviral particles produced from a nontar-
geting shRNA control plasmid encoding GFP (shGL3). Viral
transduction was efficient as indicated by 60%–90% GFP-
expressing cells in distinct experiments. To establish a positive
control for a BTIC differentiation phenotype, shGL3-transduced
BTICs were treated with BMP4 and analyzed after 6 days by
automated image analysis after fixation and nuclear staining
(Figures 2A–2C; Figure S2). To minimize potential screen arti-
facts, several parameters were combined to quantitatively
Figure 2. High-Content Lentiviral RNAi
Screen for BTIC Differentiation
(A–C) Image-based analysis of DAPI-stained
GBM-1 cells in representative wells of a 384-well
microtiter plate. Dots represent nuclei, colors
represent individual GFP fluorescence intensities
of cells upon lentiviral transduction with shGL3
(nontargeting control shRNA, A and C) or a
randomly picked shRNA (B). Note the overt pheno-
typic changes (dispersion of colonies) in BTICs
upon BMP4 treatment (C, see also Figure S2).
(D) Three-dimensional plot of a representative
primary screen experiment used for the selection
of gene knockdowns eliciting a BMP4-like differ-
entiation phenotype in BTICs (x axis, total cells
per well; y axis, mean cells per colony; z axis,
number of clusters per well). Each green dot
represents an individual shRNA lentiviral trans-
duction with R50% GFP-positive cells. The red
circle marks hit shRNAs clustering together with
BMP4-treated controls. See also Figure S2 and
Table S1.
(E–G) Representative images of GFAP staining
in shGL3-expressing cells (E), BMP4-treated
shGL3-expressing cells (F), and shTRRAP-ex-
pressing cells (G). Scale bars represent 25 mm.
(H) Top 15 gene knockdowns inducing differen-
tiation in individual BTIC lines (GBM-1 to -5).
Increasing differentiation indices (DI = % GFP-
GFAP double-positive cells/mean cells per colony;
blue bars) indicate increasing astroglial differentia-
tion and concomitant reduction of colony forma-
tion in BTICs as compared to the nontargeting
shRNA control (GL3, black bars). BMP4 treatment
is the positive control (red bars). Error bars repre-
sent the mean standard deviation of two indepen-
dent experiments.
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percentage of GFP-expressing cells, reflecting individual
transduction efficiency of the lentiviral shRNA constructs (the
threshold was set to >50% transduction efficiency), (2) the
number of total nuclei per well to monitor potential cytotoxicity
(the threshold was set to >200 nuclei/well), (3) the number of
small cell clusters containing four or fewer cells to monitor the
overt ‘‘cell dispersion’’ phenotype in the positive control (signifi-
cantly increases by R10-fold upon BMP4-induced differentia-
tion relative to control BTICs), and (4) the mean number of cells
per colony containing five or more cells to monitor self-renewal/
proliferation properties (significantly decreases byR4-fold upon
BMP4-induced differentiation compared to control BTICs). For
the kinome-wide screen, we transduced early passage GBM-1
cells with an arrayed human kinome lentiviral shRNA library
targeting 500 kinases (an average of 2.8 shRNAs per target,
The Genomics Institute of the Novartis Research Foundation,
La Jolla, CA). The cells were cultured in BTICmedium containing
FGF/EGF and data were analyzed 6 days after viral transduction.
‘‘Hits’’ were based on the smallest Euclidean distance (based on
a three-dimensional plot of the parameters described above) to
the BMP4 control falling into the 3-fold standard deviation from
the screening mean (Figure 2D; Figure S2 and Table S1). Three
independent experiments yielded 68 distinct shRNA target
genes, 10 of which (including IGF1R, MAP3K1, MAPKAPK2,and TRRAP) were each represented by two independent
shRNAs that decreased their target mRNA transcript levels by
2- to 5-fold as assessed by quantitative real-time PCR (qRT-
PCR) (Figure S2).
Next, we generated a focused library comprising all hit
shRNAs obtained from the primary screen and performed valida-
tion screens with all specimen-derived monolayer-cultured BTIC
lines (GBM-1 to -5). Two independent experiments yielded 59
out of 68 gene knockdowns that reproduced in at least one
BTIC specimen (gating criteria are described in the Supple-
mental Experimental Procedures). These hits were further cate-
gorized into groups such as tumorigenesis and cell signaling
by Ingenuity Pathway Analysis (Ingenuity Systems) (Table S2).
To evaluate the level of differentiation induced by each gene
knockdown in different GBM specimens, we included GFAP
staining as an additional parameter for image analysis and calcu-
lated a ‘‘differentiation index’’ (D.I. = percent of GFP-GFAP
double-positive cells divided by the mean cells per colony)
(Figures 2E–2H, 3A, and 3B). Of the gene knockdowns that
elicited a strong differentiation phenotype in all GBM specimens,
MLCK and TRIO have been previously reported to mediate the
invasive behavior of GBM (Kucharczak et al., 2001; Salhia
et al., 2008); PRKCG has been shown to positively regulate the
growth of glioma cell lines and has also been identified in GBM
specimens (Mishima et al., 1994; Xiao et al., 1994); and theCell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc. 39
Figure 3. Candidates Eliciting a Strong
Differentiation Phenotype across Distinct
BTIC Specimens
(A) Graph combining secondary screen hits based
on total repeats and differentiation index of
distinct shRNA candidates (D.I.). Different colors
represent reproducibility between BTIC lines
(red, hit in one specimen; blue, hit in two speci-
mens; orange, hit in three specimens; black, hit
in four specimens; green, hit in five specimens).
Red circle marks knockdown of TRRAP. The
secondary screen hits are also categorized by
their known functions in Table S2.
(B) List of shRNA candidates from the highlighted
region in (A) showing a high D.I. (>6; SD, standard
deviation) and interspecimen effects.
(C) Quantitative RT-PCR (qRT)-analysis of TRRAP
mRNA expression shows higher levels in mono-
layer-cultured BTICs (mean value of GBM-1 to
GBM-6) and xenograft tumor tissue (XG, mean of
two tissues) compared to serum-cultured glioma
cells (GL, the mean of serum-treated GBM-1,
U87, U343 is shown), normal human brain tissue
(NB, mean of three specimens), cultured human
astrocytes (AS, mean of passages 2 to 4), and
human adult neural progenitors (NP, mean of two
specimens).
(D) qRT-PCR analysis detecting knockdown of
TRRAP mRNA in lentiviral-transduced BTICs
(shCO, nontargeting; shTR1,2, two different
shRNAs targeting TRRAP; GBM-1 and -4 cells
are shown as representative examples).
(E–G) Immunostaining for TRRAP reveals nuclear
localization in Nestin-expressing monolayer
BTICs, whereas TRRAP could not be detected in
knockdown cells (shTR2-expressing cells are
shown). Scale bar represents 25 mm.
Error bars in (C) and (D) represent the standard
error of the mean.
Cell Stem Cell
TRAPP Induces Tumor-Initiating Cell Differentiationserine/threonine protein kinase STK38 has been shown to phys-
ically interact with mitogen-activated protein kinase kinase
(MEKK) (Enomoto et al., 2008), although a potential role in cancer
or brain tumors remains to be elucidated. Knockdown of
CDC2L6, LYN, TRRAP, MAP3K1, and NEK7 induced differentia-
tion in three or more GBM specimens (Figure 3B), and these
genes also showed higher mRNA expression levels (R2-fold;
MAP3K1R 5-fold) in BTICs compared to cultured human astro-
cytes as assessed by transcriptional profiling. Interestingly,
MAP3K has also been recently reported to be overexpressed
in invasive glioma cells and linked to p38 activation (Demuth
et al., 2007). The strongest differentiation phenotype was elicited
by knockdown of TRRAP, which also showed the highest repro-
ducibility among all BTIC specimens (mean D.I. = 9.3 ± 3.1;
mean D.I. of BMP4 control = 6.74 ± 3.1) (Figures 3A and 3B).
TRRAP is an adaptor protein found in multiprotein/chroma-
tin complexes sharing homology with phosphoinositide-
3-OH-kinase-related (PIKK) proteins and has been linked to
several humanmalignancies (Bashyamet al., 2005; Loukopoulos
et al., 2007; Murr et al., 2007). It is thought to regulate chromatin-
related processes, embryonic development, oncogenic transfor-
mation through c-Myc and E2F-mediated transcription, and cell
cycle progression in a cell type-specificmanner (McMahon et al.,
1998; Murr et al., 2007).40 Cell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc.Silencing of TRRAP Decreases Self-Renewal
and Proliferation in BTICs and Increases
Their Sensitivity to Apoptosis
Analysis of TRRAP expression in BTICs by qRT-PCR revealed
that all monolayer-cultured BTICs and GBM-1-derived xeno-
grafts (XG) expressed higher (>2-fold) levels of TRRAP relative
tomore differentiated cell types including serum-cultured glioma
cells (SGL; U87, U343, serum-cultured GBM-1), nontransformed
human astrocytes (AS), normal brain tissue (NB), and human
adult neural progenitors obtained from patients undergoing
epilepsy surgery (NP, culture conditions described in Walton
et al., 2006) (Figure 3C). Additionally, immunostaining for TRRAP
showed the expected nuclear localization in BTICs and coex-
pressed with Nestin (Figures 3E and 3F). We next assessed the
self-renewal capacity of TRRAP-deficient cells by determining
their sphere-forming potential upon silencing of TRRAP expres-
sion by using a commercially available lentiviral shRNA expres-
sion system (MISSION shRNA, Sigma). Two different shRNAs
(shTR1, shTR2), distinct from those used in the RNAi screen, effi-
ciently decreased TRRAP mRNA levels compared to the nontar-
geting control shRNA (shCO) as assessed by qRT-PCR and
immunocytochemistry (shTR1: 50%–70% reduction, shTR2:
60%–85% reduction, Figures 3D and 3G). All shCO-tranduced
BTICs (GBM-1 to -6) efficiently formed spheres and could be
Figure 4. Knockdown of TRRAP Induces
BTIC Differentiation and Increases Their
Sensitivity to Temozolomide
(A–C) Proliferation (A; determined by a lumines-
cence cell viability assay; results for GBM-1 cells
are shown), sphere formation (B; seeding density:
1 cell/mL), and formation of colonies from indi-
vidual cells (C) is significantly reduced in shTR1,2-
expressing BTICs.
(D and E) TRRAP-deficient cell (E) exhibiting
reduced expression of Nestin, absence of Ki67,
and a differentiated morphology in contrast to
Nestin-Ki67 double-positive control cells (D).
(F) Significant reduction of stem cell-like proper-
ties in TRRAP-deficient BTICs as indicated by
immunofluorescence quantitation (double posi-
tivity of Nestin/Sox2, Nestin/Ki67, and positivity
for GFAP and TuJ1; see also Figure S3).
(G–I) Accumulation of 53BP1 at DNA breaks (foci)
in 8Gy-irradiated GBM-1 cells after 3 hr. TRRAP-
deficient cells show absence of foci and diffuse
localization of 53BP1 (H). Scale bar represents
10 mm.
(I) Quantitation of 53BP1 foci-lacking GBM-1 cells.
(J) Quantitation of TUNEL-positive BTICs express-
ing shCO/shTR1,2 in absence (n.t.) or presence of
temozolomide (50 mM).
All error bars represent the mean standard devia-
tion of three independent experiments. Statistical
significance was calculated with a Student’s
t test (*p < 0.05, **p < 0.01).
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mL under nonadherent conditions (Figure 4B). In contrast, knock-
down of TRRAP led to overt changes in cell shape such as flat-
tened morphology and formation of cellular protrusions and in-
hibited proliferation in all BTICs (Figures 4A, 4D, and 4E).
Sphere formationwas reduced 4- to 5-fold in TRRAP knockdown
BTICs and secondary sphere formation was not observed.
Moreover, TRRAP knockdown cells failed to self-renew at
a clonal seeding density (<5 cells per well of 96-well plate),
whereas 15% of individually seeded control BTICs gave rise
to colonies (Figure 4C). The decrease in self-renewal and prolif-
eration capacity was in line with a significant decrease (>4-fold)
of Nestin/Sox2 and Nestin/Ki67 immunopositivity upon TRRAP
silencing, while GFAP staining concomitantly increased (Figures
4D and 4F; Figure S3). TuJ1 staining was consistently 2- to 3-fold
elevated in TRRAP knockdown cells.
TRRAP has been implicated in DNA repair mechanisms that
have been shown to cause resistance to radiation in glioma
stem cells (Bao et al., 2006). TRRAP may facilitate DNA repair
by chromatin remodeling, thus promoting access of repair
factors such as 53BP1 to double-strand breaks (DSBs) (Murr
et al., 2006). To investigate whether knockdown of TRRAP
affects recruitment of 53BP1 to DNA repair sites in BTICs, we
induced DSBs by irradiation of GBM-1 cells (dose: 8 Gy). TRRAP
deficiency led to a 2-fold increase in the percentage of
cells that show an absence of foci and diffuse nuclear localiza-
tion of 53BP1 relative to control cells (Figures 4G–4I). This
suggests aberrant DNA repair in TRRAP-deficient cells that
concomitantly become more prone to apoptosis as indicated
by a 2-fold increase in the percentage of TUNEL-positive cells
upon TRRAP knockdown (Figure 4J). Because DSB repair isthought to be a determinant of glioma cell sensitivity to cytotoxic
agents (Roos et al., 2007), we exposed BTICs to the methylating
brain tumor drug temozolomide. Temozolomide (50 mM) led
to a significant 2- to 3-fold increase in apoptosis in TRRAP
knockdown cells as indicated by 25%–40% TUNEL-positive
cells compared to 10% TUNEL-positive control cells after
72 hr (Figure 4J). Overall, these results suggest that TRRAP defi-
ciency elevates the sensitivity of BTICs to DNA damage and
consequently apoptosis, particularly upon exposure to cytotoxic
stimuli.
TRRAP Epigenetically Regulates Expression of CCNA2
and Cell Cycle Progression in BTICs
To investigate how knockdown of TRRAP affects the BTIC tran-
scriptome, we performed microarray gene expression analysis
of shCO- and shTR-transduced GBM-1 cells (Figure S4).
Notably, TRRAP knockdown induced downregulation (>2-fold)
of genes that are associated with cell growth and self-renewal
(e.g., CCNA2, DLL3, MKI67, SKP2, FZD1, SMO, TCF3). At the
same time, cytokines upstream of Stat signaling (LIF, IL-6) and
BMP/Smad signaling (BMP8) were upregulated (>2-fold) upon
TRRAP knockdown. Consistent with this observation, sustained
levels of phosphorylated Stat3 (both at S727 and T705) and
phosphorylated Smad1/5 were detectable in shTR-expressing
GBM-1 cells (Figure S4). All differentially expressed genes in
TRRAP knockdown cells (filtered by a 2-fold up/downregulation
relative to values in control cells) were further analyzed through
Ingenuity Pathway Analysis. Overall, the data suggest that
TRRAP acts upstream of a large number of cellular factors that
are involved in diverse signaling networks, and particularly, cell
cycle progression (G1/S and G2/M checkpoint regulation). TheCell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc. 41
Figure 5. TRRAP Silencing ReducesCCNA2
expression and Affects BTIC Cell Cycle
Progression
(A) Semiquantitative RT-PCR reveals decreased
transcription of CCNA2 but not other cyclins
(results for GBM-1 cells are shown; see also
Figure S4).
(B) Representative western blot analysis of shCO/
shTR2-expressing GBM-1 cells with antibodies
specific for E2F1,Me3K4H3, AcK9H3, phosphory-
lated (p)-RB, RB, and g-tubulin (loading control).
(C) ChIP assays reveal decreased binding of
E2F1 and reduction of ‘‘positive’’ histone marks
(AcK9H3, Me3K4H3) at the CCNA2 promoter.
Immunoprecipitated DNA was analyzed by PCR
with primers specific for the CCNA2 and GAPDH
(control) promoters, respectively.
(D) Detection and time course of CCNA2, CCND1,
and GAPDH mRNA levels in synchronized GBM-1
cells after release from the hydroxyurea block.
(E) Representative panels of cell cycle FACS anal-
ysis (Dean-Jett-Fox cell cycle modeling algorithm
of cells with DNA content between 2N and 4N)
of shCO/shTR2-expressing GBM-1 BTICs at 0, 8,
and 12 hr after release from the hydroxyurea
arrest.
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decisions (e.g., self-renewal versus differentiation) (Orford and
Scadden, 2008). The cell cycle has been shown to critically
depend on the activation of E2F transcription factor target genes
such as cyclin A2 (CCNA2) (Bracken et al., 2004; Hochegger
et al., 2008) and can be further modulated by promoter-specific
histone modifications (Blais and Dynlacht, 2007; Bracken et al.,
2004). Intriguingly, TRRAP has been implicated in E2F-mediated
transcription and positive regulation of cyclin A through partici-
pation in chromatin remodeling and histone acetylation (Herceg
et al., 2003; Murr et al., 2007).
To address the consequences of TRRAP knockdown on the
cell cycle in BTICs, we first assessed the transcriptional levels
of cyclins by semiquantitative RT-PCR. Consistent with the
microarray data, knockdown of TRRAP specifically reduced
CCNA2 mRNA levels, but not the levels of cyclin B1 (CCNB1)
and cyclin D1 (CCND1) in all adherently cultured BTIC lines. Cy-
clin E1 (CCNE1) levels were not affected in GBM-1, GBM-3,
GBM-4, and GBM-5 cells. However, GBM-2 cells showed
concomitant reduction of CCNA2 and CCNE1mRNA expression
upon TRRAP knockdown (Figure 5A; Figure S4).We next consid-42 Cell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc.ered the possibility that decreased
CCNA2 expression could result from
both decreased E2F levels and hypo-
phosphorylation of the retinoblastoma
protein (RB), thus preventing E2F-medi-
ated transcription in TRRAP knockdown
cells. However, the E2F family genes
(E2F1–E2F7) were not differentially ex-
pressed upon TRRAP knockdown, and
western blot analysis confirmed that
E2F1 protein levels were not reduced
(Figure 5B). Moreover, no decrease inthe levels of RB and phosphorylated RB protein were detected,
suggesting that reduced CCNA2 transcription likely involves
a different mechanism. Transcriptional activation is associated
with ‘‘positive’’ histone marks such as histone H3 acetylation
at lysine 9 (AcK9H3) and also trimethylation of histone H3 lysine
4 (Me3K4H3). Analysis of AcK9H3 and Me3K4H3 global protein
levels did not reveal obvious changes upon TRRAP knockdown
(Figure 5B). Therefore, we next determined whether E2F binding
and sequence-specific histone modifications are affected at the
CCNA2 promoter through chromatin immunoprecipitation anal-
ysis (ChIP). Knockdown of TRRAP led to both reduced binding
of E2F and strongly decreased histone H3 acetylation at the
CCNA2 promoter, but not at the GAPDH promoter (Figure 5C).
Cross-talk between histone deacetylation andMe3K4H3modifi-
cations has been described (Nightingale et al., 2007), and
indeed, trimethylation of H3K4 was also strongly reduced at
the CCNA2 promoter upon TRRAP knockdown. The data
suggest that TRRAP knockdown causes decreased CCNA2
expression because of a strong reduction of ‘‘positive’’ histone
marks, which may consequently affect CCNA2-dependent cell
cycle progression during S and G2 phase. TRRAP may also be
Figure 6. Knockdown of TRRAP
Suppresses BTIC Tumorigenicity In Vivo
(A and B) Hematoxylin and eosin (H&E) staining
reveals a drastically decreased xenograft tumor
formation in animals injected with TRRAP knock-
down cells compared to animals carrying control
BTICs (see also Figure S5). Scale bars represent
500 mm in (A) and 50 mm in (B, inlay).
(C) Maximal tumor areasmeasured per section are
shown for each group (shCO/shTR2-expressing
GBM-1, -3, -5; three animals per group).
(D–L) Representative immunohistochemistry (con-
focal microscopy) and quantitation of xenograft
tumors derived from shCO/shTR-expressing
BTICs. A significant reduction in the percentage
of Nestin/BrdU double-positive cells (F) and the
percentage of Ki67-positive cells (I) was detected
within xenograft lesions upon TRRAP knockdown
in all tested BTIC lines. Increase in GFAP positivity
was observed in TRRAP-deficient lesions (J com-
pared to K, Figure S5), which were preferably
located at the ventricles (V) as shown in (L), but
failed to form the large striatal (S) tumors found
in control brains. Scale bars represent 50 mm.
Error bars in (F) and (I) represent the mean
standard deviation of three independent xeno-
grafts. Statistical significance was calculated
via a Student’s t test (**p < 0.01).
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involved in mitotic entry and mitotic progression of BTICs,
although this remains to be investigated.
To investigate cell cycle phase transition and induction of
CCNA2 at the beginning of S-phase, GBM-1 cells were synchro-
nized at the G1/S interphase through treatment with hydroxy-
urea (2.5 mM for 15 h). Once released from the hydroxyurea
block, control cells accumulated CCNA2 mRNA levels over
time as assessed by semiquantitative RT-PCR (Figure 5D).
Concomitantly, cell cycle FACS revealed that control cells
were able to properly progress toward G2 phase (Figure 5E).
In contrast, TRRAP knockdown cells showed a strongly reduced
S/G2 phase progression and failed to induce CCNA2 transcrip-
tion after their release from the hydroxyurea treatment (Fig-
ure 5D), indicating that TRRAP is required for proper cell cycle
regulation in BTICs. In summary, attenuation of TRRAP may
cause the loss of stem cell-like characteristics through
numerous interrelated antiproliferative effects (e.g., cell cycleCell Stem Cell 6, 37–4arrest) and prodifferentiation effects
(e.g., elevated BMP/Smad signaling).
Knockdown of TRRAP Suppresses
BTIC Tumorigenicity
We next tested whether TRRAP knock-
down affects BTIC tumorigenicity
in vivo. To this end, we injected 60,000
shCO- and shTR2-expressing GBM-1,
GBM-3, and GBM-5 cells intracranially
into CB17/SCID mice. The animals were
kept for 8 weeks after surgery and BrdU
(1 mg BrdU in 0.1 ml PBS via i.p.) wasadministered 12 hr prior to sacrifice, thus allowing for quantifica-
tion of BrdU incorporation into S-phase tumor cells. Subsequent
histological analysis revealed that the three different shCO-
carrying BTICs gave rise to xenograft tumors that occupied large
areas of up to 12 mm2 per coronal brain section (Figure 6A). In
contrast, lesions arising from TRRAP knockdown cells were
significantly smaller with maximal areas of 0.01 to 0.05 mm2
(Figures 6B, 6C, and 6L). Interestingly, the majority of the
TRRAP-deficient lesions were located within the ventricles or
in close proximity to the ventricles. Immunohistochemical stain-
ing of tumors was performed with a human-specific Nestin anti-
body in combination with antibodies specific for BrdU, Ki67, and
GFAP. Confocal microscopy revealed a significant (>15-fold)
decrease of BrdU incorporation into shTR-carrying, Nestin-posi-
tive GBM-1, -3, and -5 cells as compared to control BTICs
(Figures 6D–6F). Additionally, Ki67 immunopositivity was also
significantly (>4-fold) decreased in TRRAP knockdown lesions
as compared to their control counterparts (Figures 6G–6I). Clear7, January 8, 2010 ª2010 Elsevier Inc. 43
Figure 7. Knockdown of TRRAP Significantly Decreases Tumor Burden and Improves Survival
(A) Noninvasive bioluminescence imaging of F-luc-tagged shCO/shTR2-expressing GBM-1 cells 10 weeks after injection into the mouse brains.
(B) Tumor burden was significantly reduced upon TRRAP silencing (Mann-Whitney Test: p = 0.0026; shCO: blue, n = 6; shTR2: red, n = 6; mean value: black bar,
median: gray bar; signal increase per animal [dot] was defined as ratio of total photons detected at the study endpoint and normalized to the starting point signal).
(C) Survival significantly improved upon TRRAP knockdown as indicated by Kaplan-Meier survival curves (log rank test: p = 0.0041).
(D and E) H&E staining of intracranial tumors confirm a decreased tumor burden in animals carrying TRRAP-deficient cells. Scale bar represents 500 mm.
(F and G) In contrast to TRRAP knockdown lesions, control tumors show a high cellularity and nuclear anaplasia. Scale bar represents 50 mm.
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knockdown xenografts in terms of overall Nestin and GFAP
immunopositivity (Figures 6J–6L; Figure S5). Themajority of cells
within control tumors were Nestin positive, whereas only a few
GFAP-positive cells could be detected per confocal field. In
contrast, the TRRAP knockdown xenograft lesions showed
decreasedNestin expression and a concomitant overall increase
of GFAP positivity, although this observation remains qualitative
because the GFAP antibody detects both murine and human
GFAP protein (Figures 6E, 6H, and 6K).
We next asked whether knockdown of TRRAP affects tumor
growth and survival over a longer study period. To this end,
30,000 shCO- and shTR2-expressing, F-luc-tagged GBM-1
BTICs were intracranially injected into CB17/SCID mice and
subsequently their growth was monitored by noninvasive biolu-
minescence imaging (Figure 7A). The control BTICs exponen-
tially expanded in all mouse brains and the tumor burden was
significantly higher (>15-fold) than that induced by the TRRAP
knockdown cells as indicated by increased luminescence over
time (total photons emitted per brain, normalized to the starting
point signal). During the whole study period, four out of six
mice injected with TRRAP knockdown cells showed no xeno-
graft expansion as indicated by a %2-fold increase in lumines-
cence signal (Figure 7B). Moderate expansion of TRRAP-defi-
cient xenografts was observed in two animals and may have
resulted from growth of cell populations with low TRRAP
knockdown efficiency after short-term selection. The majority
of control animals showed signs of morbidity between 15 and
20 weeks after transplantation and were removed from the study
(Figure 7C). In contrast, all of the mice injected with TRRAP-defi-
cient cells survived the study period of 20 weeks and appeared
healthy before sacrifice. Further histological analysis confirmed44 Cell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc.that control xenografts showed both extensive brain infiltration
and massive tumor expansion, whereas TRRAP-deficient
xenografts preferably populated the ventricle and the corpus
callosum, but failed to form striatal or cortical tumor masses
(Figures 7D and 7E). Moreover, the TRRAP-deficient lesions
exhibited a lower cellular and nuclear density relative to control
tumors (Figures 7F and 7G), which is consistent with the more
differentiated phenotype of TRRAP-deficient xenografts shown
in Figure 6. Notably, the TRRAP knockdown lesions resemble
xenografts that have been previously reported for induced differ-
entiation of BTICs upon in vivo treatment with BMP or overex-
pression of BMP receptor 1B (Lee et al., 2008; Piccirillo et al.,
2006). In summary, these findings indicate that TRRAP silencing
reproducibly suppresses the tumorigenicity of several BTIC
specimens and are consistent with our in vitro results.
DISCUSSION
Brain tumors are highly heterogeneous both phenotypically and
genotypically and are composed of several types of differenti-
ated and undifferentiated cells. Like NSCs, poorly differentiated
stem cell-like BTICs have been shown to possess the capacity of
self-renewal and multilineage differentiation and are thus able to
fuel tumor growth. One therapeutic strategy to specifically target
the stem/progenitor-like cell pool in a tumor involves forcing
these cells to undergo differentiation. For example, all-trans ret-
inoic acid and vitamin D analogs are used in the clinic for differ-
entiation therapy and treatment of acute promyelocytic leukemia
(Nowak et al., 2009). Recently BMP4 has been described as an
inducer of BTIC differentiation and a potential therapeutic agent
for the treatment of GBM (Piccirillo et al., 2006). BMPs promote
differentiation and inhibit proliferation through the BMP
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TRAPP Induces Tumor-Initiating Cell Differentiationreceptors, which, however, can be epigenetically silenced in
some cases, thus preventing BTIC differentiation (Lee et al.,
2008).
Unbiased cell-based screens of genomic, proteomic, and
chemical libraries offer a powerful tool to investigate molecular
targets and pathways controlling BTIC biology. Here, we estab-
lished a model system derived from primary GBMs and per-
formed a kinome-wide RNA interference screen to identify
factors that control the balance of BTIC maintenance and differ-
entiation.We have used conditions supporting the robust expan-
sion of both NSCs and BTICs as monolayer cultures (Aza-Blanc
et al., 2003; Fael Al-Mayhani et al., 2009; Gage et al., 1995; Lee
et al., 2006; McKay, 1997). In good agreement with our findings,
a recent study has described similar BTIC expansion in adherent
NSC conditions as well suited for high-content phenotypic
screens (Pollard et al., 2009). We established BTIC cultures
from both freshly dissociated GBMcells and dissociated primary
spheres. Notably, the cells demonstrated a homogenous Nestin/
Sox2-positive progenitor phenotype and were able to self-renew
at clonal seeding densities. Furthermore, they showed an overt
differentiation phenotype upon treatment with serum or BMP4
and, notably, xenograft tumor formation reminiscent of high-
grade gliomas. Early culture passages (passages 3 to 5) yielded
sufficient cell numbers for the kinome-wide screen. The hit rate
was 10% in the primary screen; false negatives resulting
from technical limitations of large-scale screening cannot be
excluded. Approximately one third of the hit genes have been
previously implicated in tumorigenesis (Table S2), and the
majority of the primary screen candidate gene knockdowns
reproduced in at least one specimen-derived BTIC line in the
secondary screen. Only 10% of the primary screen hits were
shared by all BTIC specimens, which is likely due to heteroge-
neity between the patient-derived BTIC lines as indicated by
their distinct gene expression profiles (Figure S1). Candidate
gene knockdowns common to different BTIC specimens (as
shown in Figure 3B) are of potential interest for further character-
ization across a larger panel of brain tumor specimens, which
may reveal their relevance within diverse glioma subtypes. In
this study, knockdown of TRRAP caused the strongest differen-
tiation phenotype among BTIC lines and was therefore charac-
terized further.
TRRAP is a large multidomain protein and a member of the
PIKK family, possessing FAT, FATC, and a Phosphoinositide-3
(PI3)-kinase-like domain. However, the kinase domain lacks
the residues that are essential for binding ATP and appears to
be catalytically inactive. TRRAP has been shown to facilitate
multiprotein assemblies such as chromatin remodeling com-
plexes, and several studies have linked the adaptor protein to
human cancer and to oncogenic factors (Murr et al., 2007).
Here, we provide several lines of evidence supporting a critical
role for TRRAP in regulating the tumorigenicity of BTICs derived
from GBM patients. Silencing of TRRAP with four different
shRNAs, delivered by two different lentiviral expression systems,
resulted in a differentiation phenotype in all BTICs. Knockdown
of TRRAP significantly decreased BTIC self-renewal and sensi-
tized the cells to temozolomide-induced apoptosis.
Transcriptional profiling revealed that TRRAP knockdown
affects numerous signaling pathway and cell cycle components.
In particular, CCNA2 expression and S/G2 progression weredependent on TRRAP. Interestingly, a recent study has demon-
strated that stem cell compartments require the function of
cyclin A, whereas its role is redundant in fibroblasts (Kalaszczyn-
ska et al., 2009). TRRAP has been shown to coordinate histone
acetyltranferase activity (Herceg et al., 2003; Murr et al., 2006,
2007; Oishi et al., 2006; Robert et al., 2006). Consistent with
this observation, knockdown of TRRAP strongly decreased
acetylation of H3K9 and trimethylation of H3K4 at the CCNA2
promoter, without affecting global levels of these interrelated
histone marks. In summary, these results suggest that the
BTIC differentiation phenotype may result from the integrated
activity of signaling networks and sequence-specific epigenetic
modifications downstream of TRRAP silencing.
Importantly, knockdown of TRRAP suppressed the tumorige-
nicity of several different BTIC lines as indicated by a strongly
reduced tumor burden and increased survival of BTIC-carrying
animals. Therefore, both the maintenance of stem cell-like char-
acteristics in vitro and tumor formation in vivo were dependent
on TRRAP expression, further strengthening the notion that
‘‘forced’’ differentiation and concomitant depletion of the BTIC
pool can suppress brain tumor formation (Lee et al., 2006,
2008; Piccirillo et al., 2006). In the light of these findings, adaptor
proteins such as TRRAP might be promising targets for the
treatment of heterogeneous, recurrent tumors. TRRAP provides
a protein-protein interaction platform for the integration of
many different regulatory factors such as GCN5, P53, BRCA1,
E2F, and MYC, and the latter has been recently shown to be
required for BTIC maintenance (Wang et al., 2008). The overall
function of TRRAP probably depends on its cellular context.
Future investigations will provide further insights into the cell
type-specific role of TRRAP and its implication in stem cell main-
tenance and brain tumorigenesis.EXPERIMENTAL PROCEDURES
Human Tissues and Cell Culture
Tumor samples classified as primary glioblastoma multiforme (GBM) were
obtained from patients undergoing surgery at the Stanford Medical Center in
accordance with Institutional Review Boards at Stanford University and The
Scripps Research Institute. All specimen-derived cells were cultured at 37C
in a humidified incubator with 5% CO2 in brain tumor-initiating cell (BTIC)
medium consisting of Neurobasal medium (Invitrogen), N2 and B27 (Invitro-
gen, 0.53 each), and human recombinant bFGF and EGF (R&D systems,
40 ng/mL each). Adherent monolayer culture was carried out by coating
plastic cell culture dishes with poly-d-lysine (Sigma) and laminin (Invitrogen;
5 mg/mL each). Culture of additional cell types is described in the Supple-
mental Information.Immunocytochemistry, Western Blotting, and Chromatin
Immunoprecipitation
Immunocytochemistry, western blotting, and ChIP assays were carried out as
previously described (Zhu et al., 2009). The antibodies are listed in the Supple-
mental Information.Animal Experiments
Female 6- to 8-week-old CB17/SCID mice were stereotactically injected with
1–6 3 104 BTICs or F-luc tagged BTICs into the striatum (2.5 mm right from
the midline, 2.5 mm anterior from bregma, and 3 mm deep) and imaged with
an IVIS200 bioluminescence imaging system (Xenogen). All animal work
complied with NIH and institutional guidelines.Cell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc. 45
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Mice were sacrificed 8 weeks or 20 weeks after injection and perfusion fixed.
After 8–24 hr postfixation in 10% NBF at 4C, the brains were either snap
frozen and cut on a cryostat (coronal, 30 mM) or processed and embedded
into paraffin followed by sectioning (coronal, 10 mM). Standard protocols
were used for Hematoxylin-Eosin staining. Immunohistochemistry was per-
formed either on a Ventana Discover XT or by floating sections staining. In
brief, floating sections were washed in PBS, treated with 3%H2O2/10%meth-
anol in PBS for 15 min, blocked (10% goat serum/0.3% Triton X-100 in PBS)
for 1 hr, and incubated with antibodies listed in the Supplemental Information.
Slides were either scanned on an Olympus/Bacus Nanozoomer at 203 and/or
analyzed by confocal microscopy.
High-Throughput Lentivirus Production and Image Analysis
The screen utilized the GNF Human Kinome Loss-of-Function Lentiviral
shRNA Library Collection targeting 500 human protein kinases with an
average of 2.8 shRNAs per target. The shRNA inserts are driven by a mouse
U6 promoter and incorporate a standard 9 bp loop (Aza-Blanc et al., 2003).
Constructs were cotransfected into HEK293T cells with packaging vectors
(pMDL.gp.RRE, pRSV-REV, and pCMV-VSVG) utilizing a high-throughput
automated lentivirus production system (ALVS, GNF Systems). Viral superna-
tants were collected 48 hr posttransfection. Titers were determined by FACS
and varied between 5 3 105 and 1.5 3 106 viral particles/mL. BTICs were
plated into 384-well microtiter plates (Greiner) under adherent conditions at
1000 cells/well. Viral transduction was performed with ALVS. Media was
changed at 24 hr posttransduction and the cells were fixed and stained after a
6 day incubation period in BTICmedium. Staining procedures were carried out
with ALVS, and subsequently images were taken and analyzed with the Opera
high-content screening system (PerkinElmer; see Supplemental Information).
Proliferation, Sphere, and Apoptosis Assay; Double-Strand Break
Induction
Mission Lentiviral shRNA clones targeting TRRAP (Sigma-Aldrich, USA) were
prepared according to the manufacturer’s specifications. After puromycin-
based selection (3–5 days, 2–5 mg/mL depending on BTIC properties), BTICs
harboring shRNAs against a control gene (luciferase; shCO) and shRNAs tar-
geting TRRAP (shTR1: CGTGTAAGAAAGGGAGAATAT; shTR2: GCCCTGTTC
TTTCGCTTTGTA) were analyzed by quantitative and/or semiquantitative
RT-PCR (see Supplemental Information). For proliferation, the cell number
was measured at day 2 and day 5 after cell seeding via the CellTiter-Glo assay
kit (Promega). For sphere assays, uncoated 24-well culture dishes were used
and 500 cells were seeded per well. Colonies arising from individual cells were
analyzed in 96-well dishes (<5 cells/well). The number of spheres or colonies
was determined 10 days after plating. For differentiation assays, cells were
plated onto poly-d-lysine/laminin-coated 24-well culture dishes (5000 cells/
well). Fixation and immunocytochemistry were performed after a one week
incubation period. To analyze recruitment of the repair protein 53BP1 to the
sites of DNA breaks, GBM-1 cells were treated with irradiation (8 Gy) and incu-
bated for 3 hr, followed by fixation and immunostaining for 53BP1. To analyze
apoptosis, DMSO (0.1%; no detectable effect on apoptosis or cell behavior) or
temozolomide (Sigma; 50 mM) was added to BTIC medium. TUNEL staining
was performed after a 72 hr incubation period via the In Situ Cell Death
Detection Kit (Roche).
Cell Cycle FACS
Cells were synchronized in BTIC medium containing 2.5 mM hydroxyurea
(Sigma) for 15 hr, then harvested, washed with PBS, fixed in 4% (v/v) PFA
for 10 min, and suspended into FACS buffer (1% FBS, 0.1% Triton X-100 in
PBS). DNA content was determined through DAPI staining (30 min, RT) and
FACS via an LSR2 instrument. Data analysis was performed with FlowJo
software.
Statistical Analysis
Statistical analyses were performed with Microsoft Excel 2007 and statistical
package R. Student’s t test (2-tailed, paired) was performed to determine
significance of in vitro results comparing BTICs expressing shCO and
shTR1,2. Mann-Whitney test was used to compare in vivo tumor growth.46 Cell Stem Cell 6, 37–47, January 8, 2010 ª2010 Elsevier Inc.A p < 0.05 was considered to represent significance (*) and p < 0.01 was
considered to be highly significant (**).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at
doi:10.1016/j.stem.2009.11.002.
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